Showing results (21-30 of 134) with videos related to

Sort By:
Pageof 14
Therapeutics and Clinical Risk Management|October 30, 2023
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective StudyYongkang Xu, Shumin Fu, Kan Liu, et al.
Frontiers in Cell and Developmental Biology|June 23, 2022
ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and InvasionShenglan Huang, Cairong Dong, Dan Li, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy|January 29, 2019
On the combination of luminescent rare earth MOF and rhodamine dopant with two sensing channels for picric acidYiLei Fan, XiangWei Cheng, Guiying Xue, et al.
Chemical Biology & Drug Design|April 16, 2023
Therapeutic potential of nitric oxide in vascular aging due to the promotion of angiogenesisJiaming Zhang, Cunrui Li, Yihua Zhang, et al.
Frontiers in Immunology|November 3, 2022
Corrigendum: A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinomaShenglan Huang, Liying Sun, Ping Hou, et al.
Frontiers in Molecular Biosciences|January 10, 2022
Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma PatientsShenglan Huang, Jian Zhang, Xiaolan Lai, et al.
Oncotargets and Therapy|June 13, 2017
Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective studyJianbing Wu, An Li, Jiajin Yang, et al.
Journal of Medicinal Chemistry|February 1, 2026
S-Nitrosation-Based Target Discovery and Drug Development: Toward a Nitric Oxide Drug 2.0 ParadigmHui Ye, Chen Zhang, Yihua Zhang, et al.
Acta Biomaterialia|May 17, 2016
Control of silk microsphere formation using polyethylene glycol (PEG)Jianbing Wu, Zhaozhu Zheng, Gang Li, et al.
Frontiers in Oncology|October 25, 2021
Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal CancerLiying Sun, Shenglan Huang, Dan Li, et al.
Pageof 14